Clinical Trial Search

Primary: Percentage of Participants With Luteinising Hormone (LH) Suppression — 100 percentage of participants

Primary: Intraocular Pressure (IOP) Change (mmHg) at Week 12 — -8.8; -8.2 mmHg

Primary: Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24 — 85.7 Percentage of participants

Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots — 13.4; 14.2; 13.1; 72.9 Percentage of…

Primary: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar…

Primary: Geometric Mean Concentration of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Measured by Enzyme-Linked Immunosorbent Assay…

Primary: Pain Experienced — 2; 2; 2 score on a scale

Primary: Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting. — 324 Participants

Primary: Ordinal Modified Rankin Scale (mRS) Score at Day 90 — 35; 31; 38; 30 Count of participants

Primary: Time From Randomization to Composite Primary Outcome — 1.5; 1.5 Years — p=0.45

Primary: Percent Change From Randomization in Body Weight at Week 88 — 14.8; -6.7 percent change — p=<.001

Primary: RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group — 7906.0; 7518.9 Titer

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 90; 180 participants

Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…

Primary: Percentage of Participants With Delirium as Assessed by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Criteria — 16.8; 26.5 Percentage of…